In 2021, the market for MicroRNA worldwide was worth $ 0.32 billion US dollars. AMR Group projects that the market will reach US$ 1.8 billion by 2031, growing at a CAGR of 19.5 percent between 2022 and 2031.

Industry Overview
MicroRNAs are minute non-coding RNA molecules found in a wide range of plants, animals, and viruses. It plays a vital role in the differentiation and development of genes through RNA silencing mechanisms and post-transcriptional. Due to their effective treatment and detection of chronic diseases which include vital infections like liver disease, coronary heart disease, and cancer. These treatments are enhancing significant traction in the healthcare business. The MiRNA research in expected for its expansion due to its important regulators of gene expression and promising biomarkers. As a novel therapeutic agent, MiRNA mimics & inhibitors are currently in preclinical development. Recent methods developed in the market include enzyme free amplification, RCA-based methods, LAMP-based methods, nanoparticle-based amplification, and DSN-based methods. In Jan. 2020, researchers worked hard in the concerned sector to develop an isothermal amplification technique for the measurement of quantitative measure of microRNA. It’s been evaluated that, in this kind of system, contamination is low, because of its dependence on the signal amplification process, whose efficiency can be improved further, as compared to other approaches. MicroRNA research is revolutionizing a technological advancement, ensuring some significant breakthroughs in microRNA technology.

Researchers and Manufacturers are inspired to develop fresh solutions in the past several years due to the technical improvements in the important phases of target gene identification, microRNA expression profiling, and validation. For example, HTG Molecular Diagnostics, Inc. recently introduced the HTG EdgeSeq mouse microRNA whole transcriptome test, a complete panel for microRNA expression profiling for the referral use in preclinical functional investigations & translational medicine. In coming years, there is a significant increase in the number of pharma and biotech firms are projected. The strong market growth can be attributed to a growing research investments in new start-ups and middle-sized enterprises to create microRNA-based medicines.

Market Dynamics
The growth of miRNA market is driven by rising incidences of chronic diseases, increasing the number of cancer cases, rising of funds in gene manipulation therapies research & innovative drug development methodologies that are used in RNAi-based approaches. In 2021, Aurora Science, an investment company, invested USD 22.46 million to InteRNA Technologies for the development of miRNAs. Additionally, in October 2021, MiRxes announced to increase its miRNA assay technology to treat multiple cancer types and other diseases. The market is expected to witness significant growth in incidence of cancer & cardiovascular diseases. Moreover, use of bioinformatics and technologically advanced systems like NGS are ready to drive the market growth and the potential of miRNAs to act as diagnostic biomarkers and anticipate to further contribute in the demand for miRNA globally. However, the challenges related to quantity and development of in-house miRNA research tools like microarrays are expected to impact the market growth. Moreover, another element driving the growth of the miRNA market share include expensive cost associated with drug research as well as the restricted therapeutic options currently accessible, which drives diagnostic businesses to develop revolutionary techniques based on miRNAs.

Technological advancements are a new development in Micro RNA research, resulting in significant progress in miRNA technology. In August 2018, HTG Molecular Diagnostics Inc., launched a comprehensive panel for miRNA expression analysis, the HTG EdgeSeq mouse miRNA whole transcriptome test, is now used in preclinical functional investigations and translational medicine. Furthermore, there is a high level of safety and toxicity Issues with development and treatment by using microRNA which may restrain the market growth.

COVID Impact
The pandemic of COVID-19 has influenced the miRNA industry in 2020. The novel coronavirus was previously thought to be predominantly a respiratory illness, but as more individuals got the virus, it developed a wide range of physiological mutations. COVID-19 infection extended beyond the lungs, affecting the cardiovascular system and causing problems in people with renal disorders. As the number of COVID-19 cases increases worldwide, so does the threat of functional renal failure in critically ill COViD-19 patients increased. A study published in PLOS Medicine, found that a high incidences of acute kidney injury in COVID-19 patients was related to higher risk of death than COVID-19. These findings suggest that patients with COVID-19 should be watched for AKI development, and preventive measures should be continuously taken. Moreover, research showed that cc-miRNAs can be employed as therapeutic agents for COVID-19, SARS-CoV, and MERS-CoV infections which had a positive impact on the miRNA market during the pandemic.

Regional Trend
Geographically, North America dominated the microRNA market and had the largest revenue share of 45.8% in 2020. The growth in this region can be attributed to various factors like the extensive R&D activities, presence of key players, and established research infrastructure for proteomics, genomics, and oncology. However, companies in the region are receiving patent approvals for their miRNA biomarkers. For instance, in May 2020, DiamiR received U.S. Patent approval for miRNA-based methods that are used for the monitoring and detection of brain aging.

In Asia Pacific, the market is expected to witness the fastest growth rate of 20.6% from 2021 to 2028 for microRNA. The growth of the market in the region can be primarily attributed to rapid advancement in genomic studies and the acceptance of new tools for supporting research endeavors. In February 2021, researchers from China identified blood microRNA as potential biomarkers for pyrrolizidine alkaloids induced hepatic sinusoidal obstruction syndrome (HSOS) by using microarray-based miRNA profiling. Additionally, the study also involved various computational microRNA-target tools for predicting the relationship between miRNA and their target mRNA.

Competitive Landscape
Key players operating in the MicroRNA Market include Agilent Technologies Inc., Biodynamics Laboratory Inc., BioGenex, Bio-Rad Laboratories, Inc., GeneCopoeia, Inc., General Electric Company, Horizon Discovery Ltd., Illumina, Inc., Merck KGaA, Miltenyi Biotech, NanoString, New England Biolabs, Norgen Biotek Corp., OriGene Technologies, Inc., Promega Corporation, Qiagen N.V., Quantabio, SeqMatic LLC, Sistemic Scotland Limited, Synlogic, and Thermo Fisher Scientific, Inc. among others.

Key USP’s-
In July 2020, Sistemic Ltd. announced the enhancement of its patent covering the use of microRNAs as predictive analyses for cellular function. The patent covers microRNA expression analysis of mesenchymal stem cells isolated from various donors to identify miRNAs that will be linked to cellular functions to support donor screening & the development of MSC-based cell therapies.

Market Segmentation
Based upon the Product and Services used in the microRNA market is segmented in Research Tools and Services. Research tools segment dominated the market in 2021 with a revenue of USD$ 252.62 million. Growth of this segment is attributed to rising incidence of chronic diseases like cancer and cardiovascular disorders. Based on the Technology, the microRNA market is segmented into Real Time Polymerase Chain Reaction, Microarray, Next Generation Sequencing (NGS) and Immunoassay. The most dominant segment among the others is Real Time Polymerase Chain Reaction technology in terms of use and revenue. Based on Application, the microRNA market is segmented into Cancer, Immunological Disorder, Infectious Diseases, Cardiovascular Disease, and Neurological Disease.
End user segment of microRNA market is further bifurcated into Academic and Research Institutes, Biopharmaceutical Companies, Contract Research Organizations and Diagnostic Centers. Academic and Research Institutes user segment dominated the market in terms of revenue owing to more inclination the use of bioinformatics and technologically advanced systems like NGS are set to drive the market growth.

By Product and Services
• Research Tools
• Services

By Technology
• Real Time Polymerase Chain Reaction
• Microarray
• Next Generation Sequencing (NGS)
• Immunoassay

By Application
• Cancer
• Immunological Disorder
• Infectious Diseases
• Cardiovascular Disease
• Neurological Disease

By End User
• Academic and Research Institutes
• Biopharmaceutical Companies
• Contract Research Organizations
• Diagnostic Centers